Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

109
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
109

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute Deterioration in a Ventilated Preterm Infant.

Journal of paediatrics and child health·2026
Same author

Progress in cell therapies for neonatal conditions: Proceedings of the Third Neonatal Cell Therapies Symposium (2025).

Pediatric research·2026
Same author

Hippocampal growth and function are reduced in the newborn following fetal growth restriction.

Brain : a journal of neurology·2026
Same author

Beyond survival: growth trajectories in necrotizing enterocolitis.

Pediatric research·2026
Same author

In vivo and ex vivo cardiovascular haemodynamic responses of preterm growth-restricted lambs to perinatal asphyxia.

Clinical science (London, England : 1979)·2025
Same author

Reducing Perinatal Mortality in Victoria, Australia: Early Insights From the Safer Baby Bundle Implementation.

The Australian & New Zealand journal of obstetrics & gynaecology·2025
Same journal

Inhibition of inflammation and senescence with azole compound C7 enables expansion of hematopoietic stem and progenitor cells.

Stem cells translational medicine·2026
Same journal

The role of endothelial colony forming cells in the treatment of limb ischaemia: challenges in clinical translation.

Stem cells translational medicine·2026
Same journal

Addressing bioenergetic deficits and restoring mitochondrial health in transplanted islets using mesenchymal stem cells.

Stem cells translational medicine·2026
Same journal

HO-1-modified umbilical cord MSCs alleviate pulmonary arterial hypertension by reducing inflammation and endothelial dysfunction.

Stem cells translational medicine·2026
Same journal

Co-culturing hiPSC-cardiomyocytes and cardiac fibroblasts enhances engineered heart tissue structure and function.

Stem cells translational medicine·2026
Same journal

The mitochondria-targeting compound PTC299 enhances megakaryocyte and platelet production.

Stem cells translational medicine·2026
See all related articles

Related Experiment Video

Updated: Nov 22, 2025

Intratracheal Instillation of Stem Cells in Term Neonatal Rats
04:27

Intratracheal Instillation of Stem Cells in Term Neonatal Rats

Published on: May 4, 2020

5.9K

A protocol for cell therapy infusion in neonates.

Elizabeth K Baker1,2, Euan M Wallace3,4, Peter G Davis1,2

  • 1Newborn Research Centre, Royal Women's Hospital, Melbourne, Victoria, Australia.

Stem Cells Translational Medicine
|January 6, 2021
PubMed
Summary
This summary is machine-generated.

Optimizing intravenous cell therapy delivery for premature infants is crucial. A refined protocol using higher albumin concentration and vertical positioning significantly improved human amnion epithelial cell (hAEC) dose delivery.

Keywords:
bronchopulmonary dysplasiacell- and tissue-based therapyhuman amnion epithelial cellsinfant, prematureinfusions, intravenous

More Related Videos

Neonatal Cardiac Scaffolds: Novel Matrices for Regenerative Studies
08:16

Neonatal Cardiac Scaffolds: Novel Matrices for Regenerative Studies

Published on: November 5, 2016

8.0K
Delivery of In Vivo Acute Intermittent Hypoxia in Neonatal Rodents to Prime Subventricular Zone-derived Neural Progenitor Cell Cultures
05:45

Delivery of In Vivo Acute Intermittent Hypoxia in Neonatal Rodents to Prime Subventricular Zone-derived Neural Progenitor Cell Cultures

Published on: November 2, 2015

7.5K

Related Experiment Videos

Last Updated: Nov 22, 2025

Intratracheal Instillation of Stem Cells in Term Neonatal Rats
04:27

Intratracheal Instillation of Stem Cells in Term Neonatal Rats

Published on: May 4, 2020

5.9K
Neonatal Cardiac Scaffolds: Novel Matrices for Regenerative Studies
08:16

Neonatal Cardiac Scaffolds: Novel Matrices for Regenerative Studies

Published on: November 5, 2016

8.0K
Delivery of In Vivo Acute Intermittent Hypoxia in Neonatal Rodents to Prime Subventricular Zone-derived Neural Progenitor Cell Cultures
05:45

Delivery of In Vivo Acute Intermittent Hypoxia in Neonatal Rodents to Prime Subventricular Zone-derived Neural Progenitor Cell Cultures

Published on: November 2, 2015

7.5K

Area of Science:

  • Neonatal medicine
  • Cell therapy
  • Biomedical engineering

Background:

  • Cell therapies show promise for neonatal conditions but lack optimized delivery protocols.
  • Intravenous (IV) delivery of cell therapies to infants has not been thoroughly evaluated.
  • Previous assumptions that prescribed cell doses equal delivered doses may be inaccurate, particularly with cell suspensions.

Purpose of the Study:

  • To quantify cell loss during IV infusion of human amnion epithelial cells (hAECs) in a neonatal model.
  • To determine an optimal IV delivery protocol for hAECs in extremely preterm infants.
  • To ensure accurate cell dose delivery in neonatal cell therapy trials.

Main Methods:

  • A laboratory model simulating pediatric IV infusion of hAECs was used.
  • Variables tested included agitation, IV-line volume, albumin concentration, and syringe orientation.
  • Flow rate was assessed after optimizing other parameters using a standard pediatric blood transfusion set.

Main Results:

  • The standard pediatric infusion protocol delivered only 17.6% ± 9% of the intended hAEC dose.
  • Optimized conditions (4% albumin, vertical syringe/IV line, 0.6 mL IV volume) achieved 99.7% ± 13% dose delivery.
  • Infusion flow rate did not significantly impact cell dose delivery.

Conclusions:

  • Standard IV infusion protocols result in significant loss of cell therapy doses.
  • A refined protocol significantly improves hAEC delivery, ensuring accurate dosing for neonatal applications.
  • This optimized protocol can serve as a foundation for future neonatal cell therapy delivery strategies.